| Aug 12 |
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 12 |
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 22 |
Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?
|
| Jun 21 |
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
|
| Jun 11 |
Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock
|
| May 14 |
Aprea Therapeutics GAAP EPS of -$0.67
|
| May 14 |
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
|
| May 13 |
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
|
| May 2 |
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
